Insights into the impact of sodium‐glucose cotransporter 2 inhibition on urinary tract malignancy: A two‐sample Mendelian randomization.

A study published in the journal Diabetes, Obesity & Metabolism suggests that long-term use of SGLT2 inhibitors, a type of medication for type 2 diabetes, may increase the risk of prostate and bladder cancer. However, there is still debate on this topic, as some studies have found no link to bladder cancer risk. The mechanisms behind this association are not well understood. Individuals considering long-term use of SGLT2 inhibitors should be aware of the potential risk, especially if they have a family history or other risk factors. Further research is needed to fully understand the relationship between SGLT2 inhibitors and urinary tumors. [Extracted from the article]